- Biological therapy in chronic rhinosinusitis with nasal polyps
In recent years, biological therapy has been in the spotlight in clinical studies on CRSwNP Biologics have proven to be efficacious in reducing nasal polyp size, alleviating CRSwNP-related symptoms, improving quality of life, and reducing the need for systemic corticosteroids or endoscopic sinus su …
- Tezspire for Nasal Polyps: A New Targeted Therapy on the . . .
June 17, 2025 Tezspire for Nasal Polyps: A New Targeted Therapy on the Horizon June 17, 2025 Anaphylm: The Needle-Free Epinephrine June 4, 2025 FDA Warning: Stopping Zyrtec or Xyzal May Cause Rebound Itching—What Allergy Patients Need to Know June 3, 2025 How the Palisades and Altadena Fires Are Affecting Your Sinuses, Lungs, and Long
- Biologic Treatments for Chronic Rhinosinusitis With Nasal . . .
This review also includes a comparative analysis of the three biologics, highlighting their efficiency and potential risks The findings suggest that dupilumab may be the most effective biologic therapy for CRSwNP, showing superior efficacy compared to mepolizumab and omalizumab in reducing nasal polyp size and improving nasal congestion
- Ultra-long-acting biological therapy for chronic . . . - The Lancet
Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common and particularly severe subset of sinonasal inflammatory disease that is characterised by benign outgrowths of the inflamed mucosa The management framework of CRSwNP substantially shifted with the introduction of biological agents 1–3 These therapies, targeting the Th2 cell cytokine pathways, drove reductions in both systemic
- Biologic Agents in Chronic Sinusitis and Nasal Polyps . . .
The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical fa
|